ARDX Strangle Strategy
ARDX (Ardelyx, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
ARDX (Ardelyx, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.58B, a beta of 0.61 versus the broader market, a 52-week range of 3.21-8.4, average daily share volume of 4.0M, a public-listing history dating back to 2014, approximately 395 full-time employees. These structural characteristics shape how ARDX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.61 indicates ARDX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on ARDX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ARDX snapshot
As of May 15, 2026, spot at $6.24, ATM IV 72.80%, IV rank 17.80%, expected move 20.87%. The strangle on ARDX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on ARDX specifically: ARDX IV at 72.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a ARDX strangle, with a market-implied 1-standard-deviation move of approximately 20.87% (roughly $1.30 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ARDX expiries trade a higher absolute premium for lower per-day decay. Position sizing on ARDX should anchor to the underlying notional of $6.24 per share and to the trader's directional view on ARDX stock.
ARDX strangle setup
The ARDX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ARDX near $6.24, the first option leg uses a $6.55 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ARDX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ARDX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.55 | N/A |
| Buy 1 | Put | $5.93 | N/A |
ARDX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ARDX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ARDX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ARDX
Strangles on ARDX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARDX chain.
ARDX thesis for this strangle
The market-implied 1-standard-deviation range for ARDX extends from approximately $4.94 on the downside to $7.54 on the upside. A ARDX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ARDX IV rank near 17.80% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ARDX at 72.80%. As a Healthcare name, ARDX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ARDX-specific events.
ARDX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ARDX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ARDX alongside the broader basket even when ARDX-specific fundamentals are unchanged. Always rebuild the position from current ARDX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ARDX?
- A strangle on ARDX is the strangle strategy applied to ARDX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ARDX stock trading near $6.24, the strikes shown on this page are snapped to the nearest listed ARDX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ARDX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ARDX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 72.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ARDX strangle?
- The breakeven for the ARDX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ARDX market-implied 1-standard-deviation expected move is approximately 20.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ARDX?
- Strangles on ARDX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ARDX chain.
- How does current ARDX implied volatility affect this strangle?
- ARDX ATM IV is at 72.80% with IV rank near 17.80%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.